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Abstract
Background: Gastric cancer is 2th most common cancer in China, and is still the second most common cause of
cancer-related death in the world. How to recognize early gastric cancer cells is still a great challenge for early
diagnosis and therapy of patients with gastric cancer. This study is aimed to develop one kind of multifunctional
nanoprobes for in vivo targeted magnetofluorescent imaging of gastric cancer.
Methods: BRCAA1 monoclonal antibody was prepared, was used as first antibody to stain 50 pairs of specimens of
gastric cancer and control normal gastric mucous tissues, and conjugated with fluorescent magnetic nanoparticles
with 50 nm in diameter, the resultant BRCAA1-conjugated fluorescent magnetic nanoprobes were characterized by
transmission electron microscopy and photoluminescence spectrometry, as-prepared nanoprobes were incubated
with gastric cancer MGC803 cells, and were injected into mice model loaded with gastric cancer of 5 mm in
diameter via tail vein, and then were imaged by fluorescence optical imaging and magnetic resonance imaging,
their biodistribution was investigated. The tissue slices were observed by fluorescent microscopy, and the
important organs such as heart, lung, kidney, brain and liver were analyzed by hematoxylin and eosin (HE) stain
method.
Results: BRCAA1 monoclonal antibody was successfully prepared, BRCAA1 protein exhibited over-expression in
64% gastric cancer tissues, no expression in control normal gastric mucous tissues, there exists statistical difference
between two groups (P < 0.01). The BRCAA1-conjugated fluorescent magnetic nanoprobes exhibit very low-
toxicity, lower magnetic intensity and lower fluorescent intensity with peak-blue-shift than pure FMNPs, could be
endocytosed by gastric cancer MGC803 cells, could target in vivo gastric cancer tissues loaded by mice, and could
be used to image gastric cancer tissues by fluorescent imaging and magnetic resonance imaging, and mainly
distributed in local gastric cancer tissues within 12 h post-injection. HE stain analysis showed that no obvious
damages were observed in important organs.
Conclusions: The high-performance BRCAA1 monoclonal antibody-conjugated fluorescent magnetic nanoparticles
can target in vivo gastric cancer cells, can be used for simultaneous magnetofluorescent imaging, and may have
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any medium, provided the original work is properly cited.great potential in applications such as dual-model imaging and local thermal therapy of early gastric cancer in near
future.
Background
Gastric cancer was once the second most common
cancer in the word [1]. Up to date, in the United
States, stomach malignancy is currently the 14th most
common cancer, and 2th most common cancer in
China [2,3]. Gastric cancer is still the second most
common cause of cancer-related death in the world,
and remains difficult to cure because most patients
present with advanced disease. Therefore, how to
recognize, track or kill early gastric cancer cells is very
key for early diagnosis and therapy of patients with
gastric cancer.
Up to date, looking for biomarkers closely associated
with gastric cancer is still an important task. Since
1998, we have been being tried to establish an early
gastric cancer pre-warning system [4], and hope to use
this pre-warning system to detect early gastric cancer
cells to recognize the patients with early gastric cancer.
Although some differently-expressed genes associated
with early gastric cancer were identified [5,6], no one
gene can be confirmed to be specific biomarker of gas-
tric cancer. Therefore, in order to recognize early gas-
tric cancer cells, we only select potential biomarkers
associated with gastric cancer, and combine nanoparti-
cles and molecular imaging techniques, try to find in
vivo early gastric cancer cells by in vivo tumor targeted
imaging. In our previous work, we screened out and
cloned BRCAA1 gene (breast cancer associated antigen
1 gene) from breast cancer cell line MCF-7cells
[AF208045, also called ARID4B (AT-rich interactive
domain-containing protein 4B)], and identified its anti-
gen epitope peptide SSKKQKRSHK [7,8]. We also pre-
pared BRCAA1 polyclonal antibody, and observed that
the BRCAA1 protein exhibited over-expression in
almost 65% clinical specimens of gastric cancer tissues
[9-11]. We also observed that BRCAA1 antigen is
over-expressed in gastric cancer cell lines such as
MKN-1, MKN-74, SGC-7901, KATO-III and MGC803
cells. Therefore, we predict that BRCAA1 protein may
be one potential targeting molecule for in vivo gastric
cancer cells.
In recent years, molecular imaging technologies based
on multi-functional nanoprobes have made great pro-
gress. For example, nanoparticles such as quantum dots,
magnetic nanoparticles and gold nanorods, etc. have
been used for molecular imaging [12-19]. So far several
small animal imaging technologies have been developed
such as optical imaging (OI) of bioluminescence (BLI),
fluorescence (FLI) and of intravital microscopy (IVM),
micro-PET, MRI and CT [20-26]. Among all these tech-
nologies, how to improve their spatial resolution and tis-
sue depth sensitivity is a great challenge. So far in vivo
tumor tissues with over 1 cm in diameter can be easily
identified by CT, MRI, PET and bioluminescence ima-
g i n g ,t u m o r sw i t hl e s st h a no re q u a lt o5m mi nd i a -
meter is very difficult to be found in clinical patients. In
our previous reports, photosensitizer-conjugated mag-
netic nanoparticles were successfully used for in vivo
simultaneous magnetofluorescent imaging and targeting
therapy [27]. However, the targeting ability of nanop-
robes was highly dependent on magnetic nanoparticles.
We also prepared a multifunctional Ribonuclease-A-
conjugated CdTe quantum dot cluster nanosystem for
synchronous cancer imaging and therapy [28], the tar-
geting ability of as-prepared nanoprobes is dependent
on RGD peptide. Some studies show that HER-2 protein
exhibits abnormal expression in 6-35% gastric cancer
tissues [29,30], and has been used as the therapeutic tar-
get for clinical patients with gastric cancer [31], there-
fore, HER-2 protein owns great potential in imaging and
therapy of gastric cancer. However, up to date, no
report shows that targeted imaging and therapy of in
vivo gastric cancer is based on biomarkers associated
with gastric cancer.
In recent years, we controllably prepared silica-coated
quantum dots and super-paramagnetic nanoparticle
composites(FMNPs) with strong fluorescent signals and
excellent magnetic properties, and have used them for
bio-labeling, tracking stem cells, bio-separation, target-
ing imaging and hyperthermia of tumors [29-32], we
also observed that as-prepared nanoparticles own good
biocompatibility and stability [33-38].
In this paper, we fully use the advantages of FMNPs
and BRCAA1 antigen, prepared monoclonal antibody
against BRCAA1 protein, and prepared BRCAA1 mono-
clonal antibody-conjugated fluorescent magnetic nanop-
robes (BRCAA1-FMNPs), employed nude mice model
loaded with gastric cancer of 5 mm in diameter and
IVIS imaging system and Magnetic Resonance Imaging,
investigated the feasibility of as-prepared nanoprobes for
non-invasive in vivo targeted dual modal imaging of gas-
tric cancer. Results show that as-prepared nanoprobes
can be used for in vivo dual-model imaging of gastric
cancer, and may have great potential in applications
such as dual-model imaging and local thermal therapy
of early gastric cancer in near future.
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Characterization of anti-BRCAA1 monoclonal Antibody
As shown in Table 1, we successfully obtained two posi-
tive clone cell lines S-200-5 and S-335-5, their titers
were different, finally we selected the anti-BRCAA1
monoclonal antibody from S-200-5 cell line as the first
antibody to stain gastric cancer tissues and control tis-
sues. We found that BRCAA1 protein exhibited over-
expression in 64% gastric cancer tissues, no expression
in normal control gastric mucous tissues, as shown in
Figure 1, there exists statistical difference between two
group (P < 0.01). This result is almost identical to our
previous report [4,9-11], which highly suggest that
BRCAA1 antigen may be selected as the potential target
for most gastric cancer, if as-prepared nanoprobes may
recognize 64% patients with early gastric cancer, it will
be very useful for diagnosis and therapy of clinical gas-
tric cancer patients.
Preparation and Characterization of BRCAA1- FMNPs
nanoprobes
As shown in Figure 2A, prepared FMNPs were composed
of silica-wrapped CdTe and magnetic nanoparticles, their
size were 50 nm or so in diameter. As shown in Figure
2D, after FMNPs were conjugated with anti-BRCAA1
antibody, as-prepared nanoprobes’ photoluminescence
(PL) intensity was lower than that of FMNPs, exhibiting
left-shift of 40 nm, which was due to decrease of the
polarization rate of the surrounding molecules, and
resulting in the decrease of stokes displacement, finally
resulting in a blue shift in the emission spectra. Similarly,
magnetic intensity of as-prepared nanoprobes was also
lower than FMNPs.
In the course of preparing BRCAA1-FMNPs nanop-
robes, we found that surface functionalization of FMNPs
was very key to conjugate anti-BRCAA1 antibody with
FMNPs via covalent bond. As shown in Figure 2C, dif-
ferent functional groups of FMNPs have different zeta-
potential values. FMNPs had negative Si-O-group, their
zeta-potential value was -34.05 mV, the FMNPs with
amino group had positive zeta-potential value of 24.80
mV, FMNPs with carboxyl group had negative zeta-
potential value of -30.50 mV. We observed that carboxyl
groups on the surface of FMNPs conjugated with anti-
BRCAA1 antibody easier than amino groups on the sur-
face of FMNPs. As shown in Table 2, the average cou-
pling rate of anti-BRCAA1 antibody with FMNPs-
COOH was 80.28%.
As-prepared nanoprobes for in vitro targeted gastric
cancer cells
Targeting ability of as-prepared nanoprobes in vitro were
observed by fluorescence microscope and calculated by
FACSCalibur Flow cytometer. As shown in Figure 3,
FMNPs randomly dispersed in the inner of the cytoplasm,
and anti-BRCAA1-FMNPs nanoprobes existed around the
Table 1 Titers of BRCAA1 Monoclonal Antibodies in
Ascites Fluid Induced by Hybridoma Clone Cells by ELISA
Antibody titer*
Clone BRCAA1 (C)-OVA ** BRCAA1 (C)-BSA ** BSA ** OVA **
S-200-5 1,024,000 1,024,000 <1,000 <1,000
S-335-5 128,000 512,000 <1,000 <1,000
*The reciprocal of ascites fluid dilution, the first dilution of ascites fluid was
1:1,000.
**The antigens were coated on ELISA plate.
Figure 1 Expression of BRCAA1 protein in gastric cancer tissues and normal control gastric mucous tissues. A: gastric cancer tissues, ×
100; B: normal control tissues, × 50.
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Page 3 of 12Figure 2 Characterization of anti-BRCAA1-FMNPs nanoprobes. A: HR-TEM picture of FMNPs; B: Magnetic property of anti-BRCAA1-FMNPs
nanoprobes; C: Zeta-potential of FMNPs with amino group, COOH, Si-O group; D: PL spectra of FMNPs conjugated with and without BRCAA1
antibody.
Table 2 Coupling rate measurement of FMNPs-anti-BRCAA1 antibody
Total concentration of the anti-BRCAA1
antibody (ng/μL)
The concentration of anti-BRCAA1 antibody in residual reaction
mixture (ng/μL)
Coupling rate
(%)
1 1000.0 197.3 80.27
2 1000.0 191.2 80.88
3 1000.0 203.0 79.70
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nanoprobes can enter into the cytoplasm of MGC803 cells
after 4 h incubation with MGC803 cells, as shown in Fig-
ure 4A, FMNPs could label 25.23% MGC803 cells, the
remain 74.77% cells could not be labeled. As shown in Fig-
ure 4B, 45.92% MGC803 cells could be labeled by the
BRCAA1-FMNPs nanoprobes. When FMNPs and anti-
BRCAA1-FMNPs nanoprobes were respectively incubated
Figure 3 In vitro fluorescence images of MGC 803 after treated with FMNPs and FMNPs-BRCAA1 nanoparticles (Magnification= × 200).
The top group of images illustrated FMNPs random distribute in the cytoplasm, the bottom group of images exhibited FMNPs-BRCAA1
dispersed around the nucleolus and had well targeting ability to the MGC803.
Figure 4 FACSCalibur Flow cytometer analysis of MGC803 labeled with FMNPs and FMNPs-BRCAA1. A: the MGC803 treated with 50 μg/
mL of FMNPs for 24 h exhibited 25.23% cell were labeled with FMNPs. B: the MGC803 treated with 50 μg/mL of FMNPs-BRCAA1 for 24 h
illustrated up to 45.92% cell were labeled with FMNPs-BRCAA1.
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we observed a lot of anti-BRCAA1-FMNPs nanoprobes
entered into MGC803 cells, few nanoprobes entered into
human fibroblast cells, few FMNPs could enter into
MGC803 cells and human fibroblast cells, which highly
suggest that anti-BRCAA1-FMNPs nanoprobes can target
MGC803 cells specifically. The Magnetic Resonance ima-
ging of MGC803 cells and human fibroblast cells incu-
bated with anti-BRCAA1-FMNPs for 4 h were shown in
Figure 5, MGC803 cells exhibited strong magnetic signal
than human fibroblast cells (HDF), which also showed
that the prepared nanoprobes can target MGC803 cells
specifically.
As-prepared nanoprobes for fluorescent imaging of in
vivo gastric cancer cells
To evaluate tumor targeted properties of anti-BRCAA1-
FMNPs nanoprobes, nude mice models loaded with
MGC-803 gastric cancer cells were prepared and moni-
tored under a non-invasive manner for 12 h by using
IVIS fluorescence imaging system.
By monitoring real-time fluorescence intensity in the
whole body, the tumor-targeting character of the anti-
BRCAA1-FMNPs probe was easily determined in the
nude mice loaded with gastric cancer MGC803 cells. As
shown in Figure 6A, the whole animals produced fluor-
escent signals within 30 min of post-injection of nanop-
robes, the subcutaneous tumor tissues could be clearly
delineated from the surrounding background tissue
between 1 h and 12 h post-injection, with maximum
contrast occurring at 6 h post-injection. Strong fluores-
cence signal was still be detected in the tumor site at 6
h post-injection, which indicated that the anti-BRCAA1-
FMNPs nanoprobes were preferentially accumulated in
the tumor tissues. Indeed based on the results in Figure
6B, the higher tumor to background ratio (TBR) value
highly suggested that as-prepared nanoprobes preferen-
tially accumulated in tumor tissues compared to normal
control tissues. This was confirmed in fluorescence
images, which showed that the fluorescence signal of as-
prepared nanoprobes in the tumor site was strongest
among all mice organs as shown in Figure 6C. In addi-
tion, after 12 h post-injection of anti-BRCAA1-FMNPs
nanoprobes, fluorescence intensity in tumor was still
observed clearly, while the uptake of prepared nanop-
robes in normal organs was not obvious. These data
h i g h l ys u g g e s tt h a tp r e p a r e dn a n o p r o b e sc a nt a r g e t
highly efficiently tumor tissues inside nude mice loaded
with gastric cancer. We also observed that those nanop-
robes in the whole mouse body almost completely dis-
appeared at 12 h post-injection, we also detected the
nanoprobes exited out from the cholecyst system (data
not shown), the time-dependent cholecyst clearance of
nanoprobes highly suggest that as-prepared nanoprobes
can not stay inside nude mice for longer time, thus, as-
prepared nanoprobes own good bio-safety.
Pathological analysis of tumor and important organs
In vitro evaluation of excised major tissues including liver,
lung, spleen, kidney, and heart, as well as the tumor, indi-
cated that the anti-BRCAA1-FMNPs probes were mainly
up-taken by the tumor tissues, which exhibited strong
fluorescence signals, as shown in Figure 7, whereas other
tissues including liver, lung, spleen and heart up-took anti-
BRCAA1-FMNPs nanoprobes very less, which furtherly
indicates that as-prepared BRCAA1-FMNPs nanoprobes
can target gastric cancer tissues. We also used HE staining
to check all organs, no obvious damages were observed in
important organs [see additional file 1].
As-prepared nanoprobes for MR Imaging of nude mice
loaded with gastric cancer
In vivo MR imaging was performed on nude mice
loaded with subcutaneous gastric cancer at 12 h post-
injection. Representative images of T2 maps were shown
in Figure 8, after injecting the nanoprobes, a significant
change in signal intensity was observed in some regions
of tumors, indicating that there existed accumulation of
the nanoprobes in tumor site as shown in Figure 8B, as
the arrow showed. As a control, after the mice model
with gastric cancer were injected FMNPs for 12 h, the
mice were performed MR imaging, which did not show
intensive signal in tumor area (Figure 8A).
Potential mechanism of targeting imaging
In recent years, molecular imaging technologies have
been used for real-time and non-invasive imaging of in
Figure 5 MR imaging of MGC803 cells and HDF cells.A :
MGC803 cells with anti-BRCAA1-FMNPs. B:HDF cells with anti-
BRCAA1-FMNPs. C: MGC803 cells with only FMNPs.
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due to their unique photoluminescent properties, have
been used for bio-labeling and fluorescent imaging
[11-13,33,43], but quantum dots’ toxicity limited their
application in human body, so far some safe quantum
dots are being developed. Magnetic nanoparticles have
also been used as contrast reagent for MR imaging
[15,33,36]. At the same time, combination of two ima-
ging modalities provides the advantages of both than
using one method, which would provide comprehensive
information on tumor localization, environment, and
status.
In this study, we designed and prepared a novel ima-
ging probe, which was composed of silicon-wrapped
quantum dots and magnetic nanoparticles with the aim
of enhancing their biocompatibility. Our results show
that prepared silicon-wrapped quantum dots and mag-
netic nanoparticles are very stable, and own strong
Figure 6 In vivo fluorescence images of tumor accumulation and tissue distribution for FMNPs-BRCAA1 nanoparticles in MGC803
human gastric tumor-bearing athymic nude mice.A ,In vivo fluorescence images of athymic nude mice bearing. MGC803 human gastric
tumor was obtained after injection of FMNPs-BRCAA1 nanoparticles at different time point. The tumor location is specified with an arrow. A-1: 0
h, A-2:0.5 h, A-3:1 h, A-4:3 h, A-5:6 h, A-6:12 h. B, TBR [Tissue to background (muscle) ratio] value. The TBR value was determined as follows: TBR
= (Tumor signal-background signal)/(background signal). C, Ex vivo fluorescence images of dissected organs and tumor of mice bearing MGC803
human gastric tumor sacrificed at 12 h after injection of FMNPs-BRCAA1 nanoparticles. The fluorescence images of dissected organs and tumor
were obtained using a fluorescence imaging technique with a 630 nm emission filter. D, Biodistribution of anti- BRCAA1-FMNPs in mice after
intravenous injection. Several time points after injection, iron amounts in tissue samples were evaluated by ICP mass spectrometry (n = 3).
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strong fluorescent signals of as-prepared nanoprobes, we
successfully obtained the fluorescent images of in vivo
gastric cancer tissues with 5 mm in diameter in nude
mice model. Using the strong magnetic signals of as-
prepared nanoprobes, we also successfully obtained MR
images of in vivo gastric cancer tissues with 5 mm in
diameter in nude mice model. Compared with previous
reports, bigger size of tumor tissues (>5 mm ) could be
easily imaged by using fluorescent imaging and MRI
imaging, as a contrast, our results showed that as-pre-
pared nanoprobes can detect smaller size of tumor tis-
sues (less 5 mm in diameter), which markedly improved
the sensitivity of detection method. Our result also is
the first time to report dual-modal targeting imaging of
in vivo gastric cancer tissues.
How to target in vivo gastric cancer tissues is also a
challengeable problem. Up to date, no specific gastric
cancer biomarkers were reported. Although HER-2 pro-
tein was confirmed to have positive expression in 6-35%
of gastric cancer tissues [28-31], HER-2 protein also
exhibits over-expression in many tumor tissues such as
breast cancer, lung cancer, colon cancer, etc, therefore
HER-2 should not be specific biomarker for gastric can-
cer. Our results showed that BRCAA1 antigen is only
over-expressed in 64% or so of gastric cancer tissues
from clinical surgery patients, we also confirmed that
BRCAA1 antigen is over-expressed in some gastric can-
cer cell lines such as MKN-1, MKN-74, SGC-7901,
KATO-III and MGC803 [6-9]. We used MGC803 cells
to prepare nude mice model loaded with gastric cancer,
and successfully observed that as-prepared nanoprobes
preferentially accumulated in tumor tissues compared
with normal control tissues, and as the post-injection
time increased. We also observed that injected nanop-
robes in the whole body exhibited the time-dependent
clearance and the fluorescent signals gradually decreased
as the time elapsed due to the liver-cholecyst excretion
system and kidney clearness of as-prepared nanoprobes.
Several reports showed that kidney only clear nanoparti-
cles with 5 nm in diameter, in our study, we observed
that as-prepared nanoprobes with 50 nm in diameter
also could be cleared within 12 h. This concrete
mechanism is under way.
Nanoprobe biosafety is also an important problem
[44], which decides the application prospect of as-pre-
pared nanoprobes. Our results fully showed that as-pre-
pared nanoprobes did not damage important organs
including liver, kidney, heart, lung, etc, also did not
exhibit long-term staying in important organs, which
highly suggest that as-prepared nanoprobes own good
biocompatibility, and have great potential in applications
such as dual model imaging and selective therapy of
early gastric cancer.
Conclusion
We successfully prepared a novel anti-BRCAA1-FMNPs
nanoprobes, which can be used for in vivo two modal
imaging such as fluorescent imaging and magnetic reso-
nance imaging, and own an obviously specific targeting
ability toward a gastric cancer tissues with 5 mm in dia-
meter during 0.5 h and 12 h of post-injection, and own
good biocompatibility. This should be first report. The
as-prepared multifunctional nanoprobes also can be
used for hyperthermia therapy of gastric cancer under
in vitro alternating magnetic field irradiation, and have
great potential in applications such as simultaneous ima-
ging and targeting therapy of clinical gastric cancer in
near future.
Materials and methods
Preparation of anti-BRCAA1 monoclonal Antibodies
Animal experiments were performed according to
Guidelines for Animal Care and Use Committee, Shang-
hai Jiao Tong University. Monoclonal antibodies were
prepared against a purified fusion protein BRCAA1.
Figure 7 Result of Immunofluorescence Analysis.A ,t u m o r
tissue. B, liver. (Magnification= × 200).
Figure 8 MRI image of mice. A, FMNPs without coupling BRCAA1
B, FMNPs coupled with BRCAA1
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from the Shanghai LAC Laboratory Animal Co. Ltd.,
Chinese Academy of Sciences (Shanghai, China). The
mice were immunized by intraperitoneal injection with
50 μg of purified BRCAA1 protein which was emulsified
with an equal volume of Freund’s complete adjuvant.
Three further injections were administered using incom-
plete adjuvant every two weeks. Three days after the last
injection, the spleen cells of the mice were harvested
and fused with the Sp 2/0 mouse myeloma cell line.
After 10-14 days, the culture supernatants were
screened with an ELISA test in which the solid phase
was coated with the recombinant BRCAA1 protein (2
μg/mL) used for the immunization. In the screening
process, the monoclonal antibodies to bind with coated
BRCAA1 protein were selected. By twice limiting dilu-
tion, positive colonies were subcloned. Ascitic fluids
were harvested from the mice primed with a 0.5 mL
intraperitoneal injection of Pristane and then injected
with 10
6 hybridoma cells. The class and subclass of each
mAb were determined using a mouse monoclonal anti-
body isotyping kit (Hy Cult Biotechnology B.V., Nether-
lands). The mAbs were purified from the mouse ascetic
fluids using a protein G-Sepharose 4FF (Pharmacia,
Uppsala, Sweden) column according to the manufac-
turer’s instructions to remove components which might
interfere with the biopanning experiments. The antibody
titers were determined by ELISA methods [45]. Finally
one of prepared anti-BRCAA1 monoclonal antibodies
was used as first antibody to stain 50 specimens of gas-
tric cancer and control gastric mucous tissues, which
were collected from Changzheng Hospital and No.1
People Hospital in Shanghai and identified by pathologi-
cal examination.
Preparation and Surface Functionalization of FMNPs
Preparation of Fe3O4 nanoparticles was based on co-
precipitation of ferrous and ferric ion solutions (1:2
molar ratio) [46-49]. CdTe nanocrystals were synthe-
sized as follows according to our previous report: CdCl2
(5 mmol) was dissolved in 110 ml of water, and 12
mmol of TGA were added under stirring, followed by
adjusting the pH to 11 by dropwise addition of 1 M
NaOH solution. The mixed solution was placed in a
three-necked flask deaerated by N2 bubbling for 30 min.
Under stirring, 2.5 mmol of oxygen-free NaHTe solution
was injected into the three-necked flask, which was
freshly prepared from tellurium powder and NaBH4
(molar rate of 1:2) in water at 0°C. The resulting solu-
t i o nw a sa b o u t4m g / m l ,a n dt h e3 . 5n md i a m e t e rp r o -
duct emitted with a maximum around 630 nm.
Fluorescent magnetic nanoparticles (FMNPs) were pre-
pared using the reverse microemulsion approach. Before
coupling the FMNPs with the BRCAA1, we first
functionalized the surface functional group of FMNPs as
carboxyl group. 95 mL ethanol and 2 mL 3-Aminopro-
pyltriethoxysilane (APS) were added to form a mixed
solution and allowed to react at room temperature for
24 h. The aminosilane-modified FMNPs were separated
by permanent magnet and were washed with deionized
water three times. Then redispersed the FMNPs-NH2 in
100 mL Dimethylformamide (DMF), added excessive
succinic anhydride to form a mixed solution and react
at room temperature for 24 h. The carboxyl-modified
FMNPs were separated by permanent magnet again and
washed with deionized water three times.
Preparation and characterization of BRCAA1 antibody-
conjugated FMNPs
We used two-step process to obtain stable anti-
BRCAA1-FMNPs conjugation [48,49]. 1.5 mg FMNPs-
COOH solution was dispersed in 2 mL pH7 PBS buffer,
and was sonicated for 10 min. Then we mixed 1 mL of
fresh 400 mM EDC and 100 mM NHSS in pH 6.0 MES
buffer and rotated it at room temperature for 15 min.
After this, the resulting solution was separated by mag-
netic field and 1 mg/mL BRCAA1 monoclonal antibody
were added to the above mixture, stirred in dark place
for 2 h. To remove free BRCAA1, the residual reaction
mixture was separated by magnetic field and the solid
remaining was washed with 1 mL PBS buffer three
times. Finally, 1 mL 0.05% Tween-20/PBS was added to
the BRCAA1-FMNPs conjugation and the final bio-con-
jugation was stored at 4°C. When we used, this
BRCAA1-FMNPs conjugation should be diluted with
PBS/0.05% Tween-20. Then we used the Nano Drop
device to quantify the coupling rate of BRCAA1 anti-
body with FMNPs-COOH. Before coupling reaction, we
measured the total concentration of BRCAA1 antibody.
After coupling reaction, we measured the BRCAA1 anti-
body concentration in residual reaction mixture and cal-
culated the coupling rate according the equation:
Coupling (%) = (1-Concentration of BRCAA1 antibody
in residual reaction mixture/Total concentration of
BRCAA1 antibody) × 100.
The as-prepared nanoprobes and pure FMNPs were
characterized by transmission electron microscopy and
photoluminescence (PL) spectrometry, and Zeta poten-
tial analyzer.
Nanoprobes for in Vitro targeting imaging of gastric
cancer cells
Gastric cancer cell line MGC803 cells with over-
expressed BRCAA1 protein were used as target cells,
human fibroblast cells without expressed BRCAA1 pro-
tein was used as control, were cultured and collected,
and then were treated with 50 μg/mL BRCAA1-FMNPs
nanoprobes and cultured in a humidified 5% CO2
Wang et al. Journal of Nanobiotechnology 2011, 9:23
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MGC803 and human fibroblast cells were treated with
FMNPs as the control group. Afterward, the cells were
rinsed with PBS three times, and then fixed cells with
2.5% glutaraldehyde solution for 30 min. For nuclear
counterstaining, MGC803 were incubated with 1 mM
Hoechst 33258 in PBS for 5 min. The cells were
observed by fluorescence microscope (NIKON TS100-
F), and imaged by GE HDX 3.0T MR imaging instru-
ment equipped with ParaVision 3.0 software.
We also used the Flow cytometer to evaluate the gas-
tric cancer cell targeting ability of BRCAA1-FMNPs
nanoprobes. MGC803 cells were treated with 50 μg/mL
BRCAA1-FMNPs or FMNPs and harvested after 4 h,
and then we fixed the cells with 70% ethanol/PBS for 30
min on ice. Approximately 4 × 10
5 cells were centri-
f u g e da n dr e s u s p e n d e dw i t hP B S ,w h i c hw e r ek e p to n
ice until analysis. The number of cells which have been
labeled with BRCAA1-FMNPs conjugation or FMNPs
were analyzed by BD FACS Calibur Flow cytometer.
Nanoprobes for fluorescence imaging of nude mode
loaded with gastric cancer
Animal experiments were performed according to
Guidelines for Animal Care and Use Committee, Shang-
hai Jiao Tong University. Male athymic nude mice were
obtained from Shanghai LAC Laboratory Animal Co.
Ltd., Chinese Academy of Sciences (Shanghai, China).
MGC-803 cells (1 × 10
6) were injected subcutaneously
i n t ot h er i g h ta n t e r i o rf l a n ka r e ao fm a l en u d em i c e
with 4 to 5 weeks ages. Tumors were allowed to grow
to a diameter of approximately 5 mm. At that point,
about 40 μg BRCAA1-FMNPs nanoprobes was injected
into the mice (n = 3) via the tail vein. Mice were respec-
tively monitored in a non-invasive manner at 0.5, 1, 3, 6,
and 12 h to get fluorescence images. Then, tumor and
major organs were collected, and were placed on black
papers, and subjected to IVIS Lumina imaging system
(Xenogen) with emission wavelengths of 630 nm. The
fluorescence images [33] were acquired and total fluor-
escence flux for each sample was obtained. For the con-
trol experiment, mice (n = 3) were injected via tail vein
with 40 μg of FMNPs and subjected to optical imaging
at various time points post-injection. Identical illumina-
tion settings (e.g., lamp voltage, filter, exposure time)
were used in all animal imaging experiments.
Nanoprobes for MR imaging of nude mice loaded with
Gastric Cancer
For MR imaging [33], gastric MGC-803 cells (1 × 10
6)
were injected subcutaneously into the right anterior
f l a n ka r e ao fm a l en u d em i c e( n = 3) with 4 to 5 weeks
ages. After tumors reached approximately 5 mm in dia-
meter, mice were injected with the BRCAA1-FMNPs
nanoprobes. MR imaging was performed within 12 h
after injections on animals anesthetized with 0.4% pen-
tobarbital. MR imaging was performed using 3.0T field
intensity by GE HDX 3.0T MR imaging instrument
equipped with GE Signa Excite 3.0T MRI software. The
imaging protocol consisted of coronal and transverse
T2- weighted spin echo (SE) pulse sequences. To pro-
duce T2 maps, the following imaging parameters were
used: TR/TE = 1000/10, 20, 30, 40, 50, 60, 70, 80 ms;
FOV= 8.0 cm; NEX = 2; slice thickness= 2.0 mm. The
mice (n = 3) model with gastric tumor performed MR
imaging and injected FMNPs without labeling BRCAA1
were used for the negative control. Representative T2
maps of the animals loaded with tumors treated with
FMNPs and BRCAA1-FMNPs, respectively. Coronal
images showed a significant signal in BRCAA1-over-
expressed tumors within 12 h after administration of the
BRCAA1-FMNPs nanoprobes.
Fluorescence microscopy observation and
immunofluorescence analysis
To compare the distributions of as-prepared nanoprobes
in tissue and tumor, the mice in test group were eutha-
nized after in vivo imaging. For histological evaluation,
excised tumor and important organs were frozen and
embedded by medium at -20°C, and then were sectioned
into 8 μm slices, which were used for fluorescence
examination under inverted fluorescence microscope
(Olympus IX71) equipped with digital camera and
immunohistochemical study with BRCAA1 antibody.
Digital images were processed with self-software (Image-
Pro Plus Version6.3). The important organ slices from
heart, lung, kidney, brain and liver were analyzed by
hematoxylin and eosin(HE) stain method.
Statistical Analysis
Each experiment was repeated three times in duplicate.
The results were presented as mean ± SD. Statistical dif-
ferences were evaluated using the t-test and considered
significance at P < 0.05.
Additional material
Additional file 1: The results of important organs stained by HE A:
heart; B:liver; C:spleen; D:lung; E:kidney; F: brain
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